FDA cleared IB Neuro™ provides a significant leap in magnetic resonance (MR) perfusion analysis. The technology is based on over 10 years of award winning research. During that time, more than 1,200 perfusion studies were performed in over 700 consenting patients with brain tumors under institutional review board (IRB) approved protocols.  IB Neuro™ analyzes dynamically acquired MR datasets and generates parametric maps of the brain that include relative cerebral blood volume (rCBV), blood flow (CBF), and mean transit time (MTT).  IB Neuro™ v1.0 software is currently available for the aycan workstation OsiriXPRO and OsiriX applications.  IB Neuro is compliant with healthcare standards such as DICOM and easily integrates into existing medical image visualization systems.  

Features:

• Platform-independent library allows for seamless integration into existing server and workstation applications.
• Instantaneously computes and displays a complete set of perfusion maps from dynamic susceptibility contrast MR imaging data using push-button processing including; rCBV, CBF, MTT, and TTP
• Automatically corrects for artifacts in rCBV maps caused by contrast agent leakage across disruptions in the blood brain barrier 
• Displays the dynamic MR signal time course for any chosen brain location
• Automatically exports perfusion parameter maps to the same medical imaging examination in DICOM compatible format
• Automatically generates a report with summary statistics
• Integrates with multiple PACS to assess data and distribute results
• Normalizes perfusion parameters to Normal Appearing White Matter (NAWM) to facilitate comparisons across serial imaging studies in the same patient, and comparisons between patients
• Automated selection of arterial input functions (AIFs) for CBF

Dynamic susceptibility contrast (DSC) MRI methods that allow the creation of relative cerebral blood volume (rCBV) maps have the potential to provide more specific information about brain tumor biology and vasculature than compared to standard anatomical MR images.  Several laboratories have demonstrated the feasibility of determining rCBV in patients with brain tumors. It has been shown that MRI-derived rCBV may:  1) better differentiate histologic brain tumor types than conventional MRI; 2) provide information to predict glial tumor grade; and 3) may even predict survival better than conventional histopathological tumor grading.  In addition, rCBV maps may aid in the differentiation of post-treatment changes from tumor recurrence, and predict local recurrence or malignant transformation earlier than conventional anatomical MR imaging.

Despite widespread and well-published potential, the incorporation of MR perfusion imaging into mainstream clinical practice has been impeded. One explanation for this slow incorporation is that the accuracy of such perfusion maps can be confounded by leakage of contrast agent from the vessels into the adjacent tissue.  Most of the available DSC post-processing software tools do not incorporate algorithms to correct for this contrast leakage effect and provide widely varying results. The DSC post-processing in IB NeuroTM incorporates leakage correction algorithms that are based on over 12 years of scientific and clinical research.  A recent, award-winning comparison study demonstrated that the post-processing method is the superior choice for brain tumor MR perfusion imaging.

IB Neuro v1.0 has been verified for compatibility with:

• aycan workstation OsiriX^PRO 1.2.019 (32-bit) on Mac OS X 10.5 (Intel)
• OsiriX 2.7.5 (32-bit) on Mac OS X 10.4 (Intel, PPC) (32-bit)
• OsiriX 3.0 (32- and 64-bit) on Mac OS X 10.5 (Intel)
• OsiriX 3.1 (32- and 64- bit) on Mac OS X 10.5 (Intel)

IB Neuro™ v1.1

Based upon the same award-winning DSC MR perfusion technology, IB Neuro™ v1.1 contains significant enhancements over the prior version, including:

• CT perfusion functionality
• Longitudinal reporting capability
• Ability to output maps fused to anatomical with registration

Please contact IB to learn more about IB Neuro™ v1.1!